A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

NCT02364999 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

719

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Bevacizumab-Pfizer
DRUG: Bevacizumab-EU
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Pfizer